| Name | Title | Contact Details |
|---|
PacketFabric is the Connectivity Cloud, designed from the ground up for scale, performance, programmability, elasticity, and security without compromise, enabling enterprises to build an agile cloud core that delivers optimal digital business outcomes. PacketFabric`s Network-as-a-Service (NaaS) platform leverages a massively scalable private optical network, the latest in packet switching technology, and end-to-end automation. PacketFabric delivers on-demand, private, and secure connectivity services between hundreds of premier colocation facilities and cloud providers across the globe. IT, network, and DevOps teams can deploy cloud-scale connectivity in minutes via an advanced Application Program Interface (API) and web portal. PacketFabric was recognized as the `2020 Fierce Telecom Innovation Award for Cloud Services,` named one of the `10 Hottest Networking Startups of 2020` by CRN, a Futuriom 40 Top Private Company, and a `2020 Cool Vendor in Enhanced Internet Services and Cloud Connectivity` by Gartner. PacketFabric investors include NantWorks and Digital Alpha Advisors.
Safari Law provides a legal operations managment system that helps corporate law departments save time, reduce risk, and recover costs during subpoena receipt, review, and response delivery.
Get ready to remove IT from daily worry list! Advantage Industries, top IT support company in Columbia, MD. ✅Get Free Consultation Today.
Starlight Software Solutions is an integrated suite of mobile and desktop applications that work together in real-time to streamline operations for the transportation, waste, and environmental industries. With Starlight`s live dispatch and tracking software businesses have full transparency into their inventory and driver network for on-the-fly improvements that can be managed from anywhere.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.